These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8942490)

  • 1. Two-step gonadotropin-releasing hormone agonist treatment of uterine leiomyomas: standard-dose therapy followed by reduced-dose therapy.
    Broekmans FJ; Hompes PG; Heitbrink MA; Netelenbos CC; Roos JC; Falke TM; Schoemaker J
    Am J Obstet Gynecol; 1996 Nov; 175(5):1208-16. PubMed ID: 8942490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
    Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
    Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone.
    Perl V; Marquez J; Schally AV; Comaru-Schally AM; Leal G; Zacharias S; Gomez-Lira C
    Fertil Steril; 1987 Sep; 48(3):383-9. PubMed ID: 2957235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
    Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
    Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging.
    Andreyko JL; Blumenfeld Z; Marshall LA; Monroe SE; Hricak H; Jaffe RB
    Am J Obstet Gynecol; 1988 Apr; 158(4):903-10. PubMed ID: 2966587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D-Trp-6-luteinizing hormone-releasing hormone microcapsules in the treatment of uterine leiomyomas.
    Golan A; Bukovsky I; Schneider D; Ron-el R; Herman A; Caspi E
    Fertil Steril; 1989 Sep; 52(3):406-11. PubMed ID: 2528476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study.
    Maheux R; Guilloteau C; Lemay A; Bastide A; Fazekas AT
    Am J Obstet Gynecol; 1985 Aug; 152(8):1034-8. PubMed ID: 3927734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
    Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
    Murphy AA; Kettel LM; Morales AJ; Roberts VJ; Yen SS
    J Clin Endocrinol Metab; 1993 Feb; 76(2):513-7. PubMed ID: 8432797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women.
    Nakamura Y; Yoshimura Y; Yamada H; Ubukata Y; Ando M; Suzuki M
    Fertil Steril; 1991 May; 55(5):900-5. PubMed ID: 1902420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial.
    Carr BR; Marshburn PB; Weatherall PT; Bradshaw KD; Breslau NA; Byrd W; Roark M; Steinkampf MP
    J Clin Endocrinol Metab; 1993 May; 76(5):1217-23. PubMed ID: 8496313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of symptomatic uterine leiomyoma with letrozole.
    Gurates B; Parmaksiz C; Kilic G; Celik H; Kumru S; Simsek M
    Reprod Biomed Online; 2008 Oct; 17(4):569-74. PubMed ID: 18854113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid reduction of uterine leiomyomas with monthly injections of D-Trp6-GnRH.
    van Leusden HA; Dogterom AA
    Gynecol Endocrinol; 1988 Mar; 2(1):45-51. PubMed ID: 2972173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up.
    Letterie GS; Coddington CC; Winkel CA; Shawker TH; Loriaux DL; Collins RL
    Fertil Steril; 1989 Jun; 51(6):951-6. PubMed ID: 2498132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced deoxyribonucleic acid damage and repair but unchanged apoptosis in uterine leiomyomas treated with gonadotropin-releasing hormone agonist.
    Huang SC; Chou CY; Lin YS; Tsai YC; Hsu KF; Liu CH; Huang KE
    Am J Obstet Gynecol; 1997 Aug; 177(2):417-24. PubMed ID: 9290461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of leiomyomas with luteinizing hormone-releasing hormone agonist].
    Nakamura Y; Yoshimura Y; Yamada H; Maruyama K; Nanno T; Ubukata Y; Ando M; Takahashi K; Suzuki M
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Dec; 42(12):1620-6. PubMed ID: 2126024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential reduction in the volume of leiomyoma and uterus during buserelin treatment.
    Puzigaća Z; Prelević GM; Sretenović Z
    Gynecol Endocrinol; 1994 Mar; 8(1):39-43. PubMed ID: 8059616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles.
    Palomba S; Affinito P; Di Carlo C; Bifulco G; Nappi C
    Fertil Steril; 1999 Nov; 72(5):889-95. PubMed ID: 10560995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
    Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
    Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of uterine leiomyomas in perimenopausal women with gonadotropin-releasing hormone agonists.
    Nakamura Y; Yoshimura Y
    Clin Obstet Gynecol; 1993 Sep; 36(3):660-7. PubMed ID: 8403612
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.